![Overall survival of EGFR-mutated lung adenocarcinoma patients with or... | Download Scientific Diagram Overall survival of EGFR-mutated lung adenocarcinoma patients with or... | Download Scientific Diagram](https://www.researchgate.net/publication/283077881/figure/fig4/AS:613883580526642@1523372659766/Overall-survival-of-EGFR-mutated-lung-adenocarcinoma-patients-with-or-without-the.png)
Overall survival of EGFR-mutated lung adenocarcinoma patients with or... | Download Scientific Diagram
![Cancers | Free Full-Text | Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis Cancers | Free Full-Text | Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis](https://www.mdpi.com/cancers/cancers-14-02519/article_deploy/html/images/cancers-14-02519-g001.png)
Cancers | Free Full-Text | Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
![Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419345880-gr1.jpg)
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect
![Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09421-7/MediaObjects/12885_2022_9421_Fig1_HTML.png)
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
![An exon 21 L858R EGFR mutation is associated with a decreased survival... | Download Scientific Diagram An exon 21 L858R EGFR mutation is associated with a decreased survival... | Download Scientific Diagram](https://www.researchgate.net/publication/333058241/figure/fig3/AS:758145567698948@1557767397979/An-exon-21-L858R-EGFR-mutation-is-associated-with-a-decreased-survival-rate-of-patients.png)
An exon 21 L858R EGFR mutation is associated with a decreased survival... | Download Scientific Diagram
![Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09421-7/MediaObjects/12885_2022_9421_Fig2_HTML.png)
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
![Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500218300059-gr2.jpg)
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect
![Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis](https://www.spandidos-publications.com/article_images/ol/20/3/ol-20-03-2266-g01.jpg)
Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
![Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-98275-3/MediaObjects/41598_2021_98275_Fig1_HTML.png)
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports
![Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer](https://www.spandidos-publications.com/article_images/mco/11/3/mco-11-03-0301-g00.jpg)
Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer
![Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies](https://www.frontiersin.org/files/Articles/635007/fonc-11-635007-HTML/image_m/fonc-11-635007-g001.jpg)
Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
![Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers](https://www.frontiersin.org/files/Articles/811601/fimmu-13-811601-HTML/image_m/fimmu-13-811601-g001.jpg)
Frontiers | Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers
![Cancers | Free Full-Text | A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses Cancers | Free Full-Text | A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses](https://www.mdpi.com/cancers/cancers-13-03641/article_deploy/html/images/cancers-13-03641-g004.png)
Cancers | Free Full-Text | A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
![The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-08449-w/MediaObjects/41598_2022_8449_Fig1_HTML.png)
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
![Kaplan–Meier estimates of overall survival according to EGFR status... | Download Scientific Diagram Kaplan–Meier estimates of overall survival according to EGFR status... | Download Scientific Diagram](https://www.researchgate.net/publication/264247700/figure/fig2/AS:202717017448452@1425342911248/Kaplan-Meier-estimates-of-overall-survival-according-to-EGFR-status-EGFR-mutation-and.png)
Kaplan–Meier estimates of overall survival according to EGFR status... | Download Scientific Diagram
![Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/public/attachments/8d03762d-8fab-4e85-9bf6-c5571441baf8/large/62035_anonymized_attachment_for_article_24422.png)
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology
![A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes | SpringerLink A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-021-00848-9/MediaObjects/11523_2021_848_Fig2_HTML.png)
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes | SpringerLink
![Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs](https://www.spandidos-publications.com/article_images/ol/18/1/ol-18-01-0792-g02.jpg)
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs
![Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports](https://www.jtocrr.org/cms/asset/8f4c3979-0b4b-4c52-b990-627274e985fe/gr3.jpg)
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports
![First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-02561-z/MediaObjects/41598_2021_2561_Fig1_HTML.png)
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
![Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology](https://onco-hema.healthbooktimes.org/article/36897-treatment-options-for-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations/attachment/93847.jpeg)